Electra Therapeutics, Inc. Expanded Access Policy

Expanded access, sometimes called “compassionate use,” is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product outside of clinical trials when no comparable or satisfactory therapeutic options are available.

Electra Therapeutics is dedicated to developing new therapies that can transform patient outcomes in serious or life-threatening conditions with high unmet medical need.  Consistent with our mission to bring innovative medicines broadly to patients as quickly as possible, we are focused on conducting the clinical trials necessary to gain regulatory approvals. These clinical trials provide the most effective way to assess how investigational medicines may treat a disease and are used to support regulatory approval.

At present, Electra Therapeutics is not making investigational medicines available for individual expanded access requests.

If you have additional questions, please speak with your treating physician.

If you wish to learn more about the clinical trial of ELA026 in secondary hemophagocytic lymphohistiocytosis, please see the ClinicalTrials.gov listing here.